Jounce falls on modest response data for ICOS mAb

Jounce Therapeutics Inc. (NASDAQ:JNCE) lost $3.76 (33%) to $7.47 on Monday after reporting modest response data in an update from the adaptive Phase I/II ICONIC trial of its inducible T cell co-stimulator (ICOS) agonist mAb JTX-2011 to treat advanced solid tumors. The data were presented Saturday at the American Society of Clinical Oncology meeting in Chicago.

Monday's stock

Read the full 576 word article

User Sign In